EU Clears AZN's Etcamah Combo for First-Line ER-Positive Breast Cancer
AstraZeneca secures EU approval for Etcamah in combination with a CDK4/6 inhibitor for first-line treatment of advanced ER-positive breast cancer patients.
AZN - AstraZeneca PLC
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$186.67
DETAILS
HIGH:
$216.00
LOW:
$158.00
MEDIAN:
$185.00
CONSENSUS:
$186.67
UPSIDE:
10.29%
Stock News
FTSE 100 shares to watch: Lloyds, Barclays, IAG, NatWest, GSK, AstraZeneca
The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis, the ongoing US earnings season, and a series of key UK economic releases. Market participants digested the latest jobs, inflation, and retail sales data for July, all of which could influence the Bank of England's next policy decision.
AstraZeneca 'magic' faces rare test after trial failure, share slide
AstraZeneca's long-time CEO Pascal Soriot has rarely put a foot wrong. The company's shares have more that quadrupled in price during his 14-year tenure, soaring above the wider FTSE 100 index and main British rival GSK.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 23, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
AR Asset Management Inc. Sells 4,000 Shares of Astrazeneca Plc $AZN
AR Asset Management Inc. decreased its stake in shares of Astrazeneca Plc (NYSE: AZN) by 50.0% during the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 4,000 shares of the company's stock after selling 4,000 shares during the period. AR Asset
AstraZeneca Wins EU Approval for Breast-Cancer Drug as U.S. Review Continues
The approval opens a big market for camizestrant as U.S. regulators continue to review the company's application there.
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AstraZeneca
AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)---- $AZN--AZN Investors Have Opportunity to Join AstraZeneca PLC Fraud Investigation with the Schall Law Firm.
Jefferies says September lung data can offset AstraZeneca trial failure
Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the...
Jefferies says September lung data can offset AstraZeneca trial failure
Jefferies believes detailed data on AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental lung drug tozorakimab could more than compensate investors for the recent failure of a separate heart trial. The bank has reiterated its buy rating and 17,500p price target, implying 41% upside from the current 12,380p, and flagged the 8 September presentation at the European Respiratory Society congress as the key catalyst.
Stay Ahead of the Game With Astrazeneca (AZN) Q2 Earnings: Wall Street's Insights on Key Metrics
Evaluate the expected performance of Astrazeneca (AZN) for the quarter ended June 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Biotech's takeover boom may be running out of buyers
Biotech dealmaking has reached a level this year that has already outstripped the whole of 2025, and RBC Capital Markets thinks the pace is unlikely to hold. Cumulative deal value in the first half of 2026 came to $78 billion, against $42 billion for the entirety of last year, according to the bank's half-year sector review.
Royalty Pharma acquires royalty interest in AstraZeneca's cliramitug for up to $425 million from Neurimmune
NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a portion of Neurimmune's royalty interest in AstraZeneca's cliramitug for up to $425 million, including $125 million upfront.
These major drug stocks rally after Trump's zero tariff announcement
President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.
Varon Corp expands Ballislife HYDRO into Canada through Shoot 360 partnership
Varon Corp (OTCID:OZSC) announced that Ballislife Drink Inc, its joint venture with Varon USA and Ballislife Inc, has signed a multi-year exclusive deal...
Aftermath Silver begins drilling at Berenguela copper target and Chile's Challacollo project
Aftermath Silver Ltd (TSX-V:AAG, OTCQX:AAGFF, FRA:FLM1) announced that it has started drilling at the eastern edge of its Berenguela project in Peru to test...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AstraZeneca PLC- AZN
NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC (“AstraZeneca” or the “Company”) (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
4,699 Shares in Astrazeneca Plc $AZN Purchased by Baader Bank Aktiengesellschaft
Baader Bank Aktiengesellschaft acquired a new position in Astrazeneca Plc (NYSE: AZN) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 4,699 shares of the company's stock, valued at approximately $920,000. Several other large investors have also modified
Andra AP fonden Makes New $46.60 Million Investment in Astrazeneca Plc $AZN
Andra AP fonden bought a new position in shares of Astrazeneca Plc (NYSE: AZN) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 236,302 shares of the company's stock, valued at approximately $46,603,000. Astrazeneca comprises 0.6% of Andra
Astrazeneca (AZN) Falls More Steeply Than Broader Market: What Investors Need to Know
Astrazeneca (AZN) closed the most recent trading day at $164.52, moving 2.59% from the previous trading session.
Price Targets
AstraZeneca price target raised to $108 from $95 at HSBC
$108.00
(was $179.64)
HSBC
AstraZeneca price target raised to $103 from $93 at Morgan Stanley
$103.00
(was $180.34)
Morgan Stanley
AstraZeneca price target raised to $97 from $93 at Berenberg
$97.00
(was $141.64)
Luisa Hector
·
Berenberg Bank
AstraZeneca (AZN) PT Lowered to $88 at BMO Capital
$88.00
(was $162.38)
Etzer Darout
·
BMO Capital
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
$89.00
(was $159.88)
Etzer Darout
·
BMO Capital
AstraZeneca (AZN) PT Raised to $85 at Argus
$85.00
(was $153.68)
John Eade
·
Argus Research
BMO Capital Reiterates Outperform Rating on AstraZeneca (AZN)
$82.00
(was $153.48)
Etzer Darout
·
BMO Capital
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
$79.00
(was $129.72)
Andrew Berens
·
Leerink Partners
BMO Capital Initiates Coverage On AstraZeneca with Outperform Rating, Announces Price Target of $82
$82.00
(was $139.00)
BMO Capital
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $78
$78.00
(was $130.18)
Leerink Partners
SVB Leerink Maintains Outperform on AstraZeneca, Raises Price Target to $75
$75.00
(was $134.34)
Leerink Partners